MRNA Moderna, Inc. - Common Stock
Moderna, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
और पढ़ें
Moderna, Inc. ( mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In 2026, Time ranked Moderna as number one in their World's Most Impactful Companies list.
History
Moderna was founded in 2010 by Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, Robert S. Langer, and Noubar Afeyan. Stéphane Bancel was appointed as CEO in 2011. Between 2011 and 2017, Moderna raised US$2 billion in venture capital funding. In 2024, Bancel also led marketing for the company during a transition.
Product development
In 2013, the company formed a partnership with AstraZeneca to develop treatments for cardiovascular, metabolic, and renal diseases, as well as cancer. Moderna was also awarded a $25 million grant by DARPA through a program Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT-PROTECT). Its stated goal was to develop an mRNA vaccine with the capability to suppress a global pandemic within 60 days. In January 2014, the company entered an agreement with Alexion Pharmaceuticals to develop treatments against ten diseases. In January 2014, Moderna created its first venture, Onkaido Therapeutics, to focus "exclusively on developing mRNA-based oncology treatments." It launched its second venture, Valera, in January 2015, with a focus on "viral, bacterial and parasitic infectious diseases." Employees of Valera and Moderna developed an mRNA vaccine candidate against Zika virus infection. Another venture, Elpidera, was announced in May 2015 to continue work on RNA therapies advancing Moderna's work with Alexion.
In 2015, the company formed a partnership with Merck to develop treatments for cancer, and in 2016, the company formed a partnership with Vertex Pharmaceuticals to develop treatments for cystic fibrosis. In January 2016, the Bill & Melinda Gates Foundation committed to provide at least $20 million in grant funding to the company. In 2017, Alexion terminated its partnership with Moderna after safety issues prevented their work from reaching human trials.
In July 2018, the company opened a 200,000 square foot facility in Norwood, Massachusetts for manufacturing, preclinical and clinical work. In December 2018, Moderna became a public company via the largest initial public offering of a biotechnology company in history, raising $621 million by selling 27 million shares at $23 per share.
The first mRNA vaccine developed by Moderna was for influenza in 2015, and its first antibody encoded by mRNA was in 2019. In 2023, Moderna acquired OriCiro Genomics, a Japanese manufacturer of genetic engineering tools, in its first acquisition.
In early 2023, the company in collaboration with Merck won breakthrough status from the FDA for its mRNA-4157/V940 drug candidate, a cancer vaccine.
In July 2023, the company entered into an agreement with the Chinese government to develop mRNA drugs for exclusive use in China.
In May 2024, mResvia, a mRNA respiratory syncytial virus vaccine, was approved for medical use in the United States by the Food and Drug Administration (FDA) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older, the third respiratory syncytial virus vaccine approved in the United States.
In August 2026, Mflusiva, an mRNA vaccine against influenza, intended for individuals aged 50 years of age and older, was approved for medical use in the United States.
COVID-19 vaccine
From 2020 to 2021, Moderna received $955 million from Operation Warp Speed to accelerate development of its COVID-19 vaccine, with $4.9 billion committed in total for producing 300 million vaccine doses.
In March 2020, the US Food and Drug Administration (FDA) approved clinical trials for the Moderna COVID‑19 vaccine candidate, and in December 2020, the vaccine, mRNA-1273, was issued an emergency use authorization in the United States. In 2022, it gained FDA approval both for the monovalent vaccine, Spikevax, and a bivalent booster.
In April 2022, Moderna announced plans to build a $180 million vaccine factory in Montreal, Canada, forming a 10-year partnership with the Government of Canada, Quebec, and McGill University to produce 100 million Spikevax doses annually and expand vaccine research capabilities. The plant is scheduled to supply COVID-19 vaccines in the fall of 2025.
In February 2023, the company agreed to pay $400 million to the National Institutes of Health, Dartmouth College, and Scripps Research to settle a dispute over the rights to a chemical technique that was used in the vaccine.
Legal disputes
Arbutus Biopharma filed a patent infringement lawsuit against Moderna in 2022, alleging that Arbutus developed lipid nanoparticles that enclose the Moderna vaccine's mRNA payload. In April 2023, a court affirmed a decision to cancel a patent by Arbutus Biopharma in connection with the dispute. In April 2024, however, the court issued an order that strengthened Arbutus's arguments by interpreting patents at issue in the manner Arbutus had urged.
Several legal cases between Moderna and Pfizer and BioNTech in various countries, alleging that the Pfizer–BioNTech COVID-19 vaccine violates the patent on Moderna's mRNA vaccine technology, are ongoing.
In November 2024, the British pharmaceutical company GSK plc filed a lawsuit against Moderna Inc. in a US federal court in the state of Delaware, seeking unspecified royalties alleging that the Moderna COVID-19 vaccine and RSV vaccine mResvia infringe on GSK's patents related to messenger RNA (mRNA) technology. According to the complaint, Moderna's use of lipid nanoparticles—crucial for delivering fragile mRNA into the human body—violates several GSK patents covering similar delivery innovations. This lawsuit follows a similar legal action GSK brought against Pfizer and BioNTech earlier in 2024, claiming patent infringement over their mRNA-based COVID-19 vaccine.
== Financial data ==
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
MRNA स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
MRNA स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
MRNA विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
- मजबूत खरीद 2 6.7%
- खरीदें 7 23.3%
- होल्ड 18 60.0%
- बेचें 2 6.7%
- मजबूत बिक्री 1 3.3%
12-महीने का मूल्य लक्ष्य
19 विश्लेषक · 2026-08-19Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 30 जून 2026 | $-1.97 | $-2.12 | 0.15% |
| 31 मार्च 2026 | $-3.40 | $-4.04 | 0.64% |
| 31 दिसमबर 2025 | $-2.11 | $-2.70 | 0.59% |
| 30 सितमबर 2025 | $-0.51 | $-2.15 | 1.6% |
| 30 जून 2025 | $-2.13 | $-3.03 | 0.90% |
| 31 मार्च 2025 | $-2.52 | $-3.20 | 0.68% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| RVMD | — | — | — | — | — | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 16
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B | $803M | $60M | $135M | $206M | |
| Cost of Revenue | $868M | $1.46B | $4.69B | $5.42B | $2.62B | $8M | $0 | $0 | · | |
| R&D Expense | $3.13B | $4.54B | $4.84B | $3.29B | $1.99B | $1.37B | $496M | $454M | $410M | |
| SG&A Expense | $1.02B | $1.17B | $1.55B | $1.13B | $567M | $188M | $110M | $94M | $65M | |
| Operating Expenses | $5.02B | $7.18B | $11.09B | $9.84B | $5.17B | $1.57B | $606M | $548M | $475M | |
| Operating Income | $-3.07B | $-3.94B | $-4.24B | $9.42B | $13.30B | $-763M | $-546M | $-413M | $-269M | |
| Interest Income | $314M | $425M | $421M | $200M | $18M | $25M | $39M | $27M | $15M | |
| Other Non-op | $-8M | $-87M | $-124M | $-45M | $-29M | $-6M | $-8M | $2M | $-2M | |
| Pretax Income | $-2.77B | $-3.61B | $-3.94B | $9.57B | $13.29B | $-744M | $-515M | $-384M | $-256M | |
| Income Tax | $54M | $-46M | $772M | $1.21B | $1.08B | $3M | $-1M | $326.0K | $-80.0K | |
| Net Income | $-2.82B | $-3.56B | $-4.71B | $8.36B | $12.20B | $-747M | $-514M | $-385M | $-256M | |
| EPS (Basic) | $-7.26 | $-9.28 | $-12.33 | $21.26 | $30.31 | $-1.96 | $-1.55 | · | · | |
| EPS (Diluted) | $-7.26 | $-9.28 | $-12.33 | $20.12 | $28.29 | $-1.96 | $-1.55 | · | · | |
| Shares (Basic) | 389,000,000 | 384,000,000 | 382,000,000 | 394,000,000 | 403,000,000 | 381,000,000 | 331,000,000 | · | · | |
| Shares (Diluted) | 389,000,000 | 384,000,000 | 382,000,000 | 416,000,000 | 431,000,000 | 381,000,000 | 331,000,000 | · | · | |
| EBITDA | $-2.86B | $-3.76B | $-3.62B | $9.77B | $13.53B | $-732M | $-515M | · | · |
बैलेंस शीट 28
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.60B | $1.93B | $2.91B | $3.21B | $6.85B | $2.62B | $236M | $658M | $135M | |
| Receivables | $184M | $358M | $892M | $1.39B | $3.17B | $1.39B | $5M | $12M | $12M | |
| Inventory | $153M | $117M | $202M | $949M | $1.44B | $47M | $0 | · | · | |
| Prepaid Expense | $408M | $599M | $627M | $1.20B | $728M | $252M | $19M | $28M | $13M | |
| Other Current Assets | $45M | $58M | $88M | $44M | $26M | $11M | · | · | · | |
| Current Assets | $6.54B | $8.10B | $10.32B | $13.43B | $16.07B | $6.30B | $1.13B | $1.56B | $783M | |
| PP&E (Net) | · | · | · | · | · | · | · | $212M | $139M | |
| PP&E (Gross) | · | · | · | · | · | · | · | $276M | $187M | |
| Accum. Depreciation | · | · | · | · | · | · | · | $64M | $48M | |
| Goodwill | $52M | $52M | $52M | $0 | · | · | · | · | · | |
| Intangibles | $45M | $40M | $44M | $0 | · | · | · | · | · | |
| Other Non-current Assets | $605M | $594M | $766M | $988M | $46M | $2M | $2M | $3M | $5M | |
| Total Assets | $12.34B | $14.14B | $18.43B | $25.86B | $24.67B | $7.34B | $1.59B | $1.96B | $1.08B | |
| Accounts Payable | $317M | $405M | $520M | $487M | $302M | $18M | $7M | $31M | $21M | |
| Accrued Liabilities | $1.39B | $1.43B | $1.80B | $2.10B | $1.47B | $470M | $68M | $79M | $73M | |
| Current Liabilities | $1.99B | $2.21B | $3.02B | $4.92B | $9.13B | $4.39B | $143M | $223M | $191M | |
| Capital Leases | $653M | $671M | $643M | $92M | $106M | $97M | $94M | · | · | |
| Deferred Tax | $249M | $231M | $235M | · | · | · | · | · | · | |
| Other Non-current Liabilities | $285M | $267M | $256M | $135M | $76M | $3M | $138.0K | $258.0K | $2M | |
| Total Liabilities | $3.69B | $3.24B | $4.57B | $6.74B | $10.52B | $4.78B | $415M | $432M | $459M | |
| Total Debt | $590M | · | · | · | · | · | · | · | · | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $34.0K | $33.0K | $6.0K | |
| Paid-in Capital | $1.38B | $866M | $371M | $1.17B | $4.21B | $4.80B | $2.67B | $2.54B | $72M | |
| Retained Earnings | $7.22B | $10.04B | $13.61B | $18.32B | $9.96B | $-2.24B | $-1.50B | $-1.01B | $-622M | |
| AOCI | $45M | $-10M | $-123M | $-370M | $-24M | $3M | $2M | $-1M | $-1M | |
| Stockholders' Equity | $8.65B | $10.90B | $13.85B | $19.12B | $14.14B | $2.56B | $1.18B | $1.53B | $-551M | |
| Liabilities + Equity | $12.34B | $14.14B | $18.43B | $25.86B | $24.67B | $7.34B | $1.59B | $1.96B | $1.08B | |
| Shares Outstanding | 394,000,000 | 386,000,000 | 382,000,000 | 385,000,000 | 403,000,000 | 399,000,000 | 336,536,985 | 328,798,904 | 65,206,999 |
नकदी प्रवाह 14
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $211M | $185M | $617M | $348M | $232M | $31M | $31M | $25M | $21M | |
| Stock-based Comp | $483M | $429M | $305M | $226M | $142M | $93M | $81M | $73M | $40M | |
| Deferred Tax | $10M | $-1M | $901M | $-578M | $-296M | $0 | $-1M | $0 | $0 | |
| Other Non-cash | $245M | $-56M | $-227M | $-3.38B | $1.34B | $2.65B | $-56M | · | · | |
| Operating Cash Flow | $-1.87B | $-3.00B | $-3.12B | $4.98B | $13.62B | $2.03B | $-459M | $-331M | $-331M | |
| CapEx | $192M | $1.05B | $707M | $400M | $284M | $68M | $32M | $106M | $58M | |
| Investing Cash Flow | $1.95B | $1.95B | $4.21B | $-5.18B | $-8.52B | $-1.67B | $-15M | $-373M | $417M | |
| Stock Issued | · | · | · | $0 | $0 | $1.85B | $0 | $563M | · | |
| Stock Repurchased | $2M | $0 | $1.15B | $3.33B | $857M | $0 | $0 | · | · | |
| Net Stock Activity | $-2M | $0 | $-1.15B | $-3.33B | $-857M | $1.85B | · | · | · | |
| Financing Cash Flow | $593M | $56M | $-1.38B | $-3.45B | $-873M | $2.03B | $52M | $1.23B | $168.0K | |
| Net Change in Cash | $668M | $-999M | $-289M | $-3.64B | $4.22B | $2.39B | $-422M | $523M | $86M | |
| Taxes Paid | $26M | $197M | $-357M | $2.73B | $480M | $1M | $0 | $294.0K | $398.0K | |
| Free Cash Flow | $-2.06B | $-4.05B | $-3.83B | $4.58B | $13.34B | $1.96B | $-491M | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -158.1% | -121.9% | -61.9% | 48.9% | 72.0% | -95.0% | -906.4% | · | · | |
| Net Margin | -145.2% | -110.0% | -68.8% | 43.4% | 66.1% | -93.0% | -853.7% | · | · | |
| Pretax Margin | -142.4% | -111.5% | -57.6% | 49.7% | 71.9% | -92.7% | -854.9% | · | · | |
| EBITDA Margin | -147.3% | -116.2% | -52.9% | 50.7% | 73.2% | -91.1% | -854.9% | · | · | |
| ROA | -21.3% | -21.9% | -21.3% | 33.1% | 76.2% | -16.7% | -28.5% | · | · | |
| ROE | -31.3% | -31.2% | -34.5% | 45.1% | 100.6% | -28.1% | -42.4% | · | · | |
| ROIC | -33.9% | -35.7% | -36.6% | 43.0% | 86.3% | -29.9% | -46.4% | · | · |
तरलता और शोधन क्षमता 4
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.7 | 3.4 | 2.7 | 1.8 | 1.4 | 7.9 | · | · | |
| Quick Ratio | 1.4 | 1.0 | 1.3 | 0.9 | 1.1 | 0.9 | 1.7 | · | · | |
| Debt / Equity | 0.1 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.1 | · | · | · | · | · | · | · | · |
दक्षता 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.2 | 0.3 | 0.8 | 1.2 | 0.2 | 0.0 | · | · | |
| Inventory Turnover | 6.4 | 9.2 | 8.2 | 4.5 | 3.5 | 0.3 | · | · | · | |
| Receivables Turnover | 7.2 | 5.2 | 6.0 | 8.4 | 8.1 | 1.2 | 8.6 | · | · |
विकास दरें 5
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -39.9% | -52.8% | -64.5% | 4.3% | 2200.2% | · | · | · | · | |
| Revenue CAGR 3Y | -53.4% | -44.0% | 104.3% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.3% | · | · | · | · | · | · | · | · | |
| EPS YoY | · | · | · | -28.9% | · | · | · | · | · | |
| Net Income YoY | · | · | · | -31.5% | · | · | · | · | · |
मूल्यांकन (TTM) 14
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B | $803M | $60M | $135M | · | |
| Net Income TTM | $-2.82B | $-3.56B | $-4.71B | $8.36B | $12.20B | $-747M | $-514M | $-385M | · | |
| Market Cap | $11.62B | $16.05B | $37.99B | $69.15B | $102.35B | $41.66B | $6.58B | · | · | |
| Enterprise Value | $9.61B | · | · | · | · | · | · | · | · | |
| P/E | -4.1 | -4.5 | -8.1 | 8.9 | 9.0 | -53.3 | -12.6 | · | · | |
| P/S | 6.0 | 5.0 | 5.5 | 3.6 | 5.5 | 51.9 | 109.7 | · | · | |
| P/B | 1.3 | 1.5 | 2.7 | 3.6 | 7.2 | 16.3 | 5.6 | · | · | |
| P / Tangible Book | 1.4 | 1.5 | 2.8 | 3.6 | 7.2 | 16.3 | · | · | · | |
| P / Cash Flow | -6.2 | -5.3 | -12.2 | 13.9 | 7.5 | 20.6 | -14.3 | · | · | |
| P / FCF | -5.6 | -4.0 | -9.9 | 15.1 | 7.7 | 21.3 | -13.4 | · | · | |
| EV / EBITDA | -3.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -4.7 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 4.9 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -24.6% | -22.3% | -12.4% | 11.2% | 11.1% | -1.9% | -7.9% | · | · |
आय विवरण 16
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $145M | $389M | $678M | $1.02B | $142M | $108M | $966M | $1.86B | $241M | $167M | $2.81B | $1.83B | $344M | $1.86B | $5.08B | $3.36B | |
| Cost of Revenue | $93M | $955M | $452M | $207M | $119M | $90M | $739M | $514M | $115M | $96M | $929M | $2.24B | $731M | $792M | $1.92B | $1.10B | |
| R&D Expense | $651M | $649M | $775M | $801M | $700M | $856M | $1.12B | $1.14B | $1.22B | $1.06B | $1.41B | $1.16B | $1.15B | $1.13B | $1.21B | $820M | |
| SG&A Expense | $216M | $173M | $308M | $268M | $230M | $212M | $351M | $281M | $268M | $274M | $470M | $442M | $332M | $305M | $375M | $278M | |
| Operating Expenses | $960M | $1.78B | $1.53B | $1.28B | $1.05B | $1.16B | $2.21B | $1.93B | $1.60B | $1.43B | $2.81B | $3.84B | $2.21B | $2.23B | $3.50B | $2.20B | |
| Operating Income | $-815M | $-1.39B | $-857M | $-260M | $-907M | $-1.05B | $-1.25B | $-70M | $-1.36B | $-1.27B | $6M | $-2.01B | $-1.87B | $-366M | $1.58B | $1.17B | |
| Interest Income | $67M | $72M | $70M | $73M | $81M | $90M | $91M | $103M | $111M | $120M | $103M | $105M | $104M | $109M | $87M | $58M | |
| Other Non-op | $-19M | $-18M | $-12M | $0 | $8M | $-4M | $-29M | $-12M | $-27M | $-19M | $-39M | $-51M | $14M | $-48M | $-12M | $-7M | |
| Pretax Income | $-767M | $-1.33B | $-799M | $-187M | $-818M | $-964M | $-1.18B | $21M | $-1.28B | $-1.17B | $70M | $-1.96B | $-1.75B | $-305M | $1.66B | $1.22B | |
| Income Tax | $15M | $9M | $27M | $13M | $7M | $7M | $-64M | $8M | $0 | $10M | $-147M | $1.67B | $-369M | $-384M | $190M | $174M | |
| Net Income | $-782M | $-1.34B | $-826M | $-200M | $-825M | $-971M | $-1.12B | $13M | $-1.28B | $-1.18B | $217M | $-3.63B | $-1.38B | $79M | $1.47B | $1.04B | |
| EPS (Basic) | $-1.97 | $-3.40 | $-2.10 | $-0.51 | $-2.13 | $-2.52 | $-2.91 | $0.03 | $-3.33 | $-3.07 | $0.62 | $-9.53 | $-3.62 | $0.20 | $3.95 | $2.67 | |
| EPS (Diluted) | $-1.97 | $-3.40 | $-2.10 | $-0.51 | $-2.13 | $-2.52 | $-2.91 | $0.03 | $-3.33 | $-3.07 | $0.63 | $-9.53 | $-3.62 | $0.19 | $3.77 | $2.53 | |
| Shares (Basic) | 398,000,000 | 395,000,000 | -775,000,000 | 390,000,000 | 388,000,000 | 386,000,000 | -767,000,000 | 385,000,000 | 384,000,000 | 382,000,000 | -766,000,000 | 381,000,000 | 381,000,000 | 386,000,000 | -794,000,000 | 390,000,000 | |
| Shares (Diluted) | 398,000,000 | 395,000,000 | -775,000,000 | 390,000,000 | 388,000,000 | 386,000,000 | -781,000,000 | 399,000,000 | 384,000,000 | 382,000,000 | -785,000,000 | 381,000,000 | 381,000,000 | 405,000,000 | -841,000,000 | 412,000,000 | |
| EBITDA | $-759M | $-1.33B | · | $-209M | $-851M | $-1.01B | · | $-19M | $-1.32B | $-1.23B | · | $-1.77B | $-1.78B | $-288M | · | $1.28B |
बैलेंस शीट 25
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.72B | $1.91B | $2.60B | $1.13B | $1.28B | $1.62B | $1.93B | $1.64B | $2.48B | $2.05B | $2.91B | $2.93B | $3.80B | $3.44B | $3.21B | $3.03B | |
| Receivables | $17M | $71M | $184M | $1.05B | $36M | $78M | $358M | $1.56B | $163M | $137M | · | $1.87B | $232M | $1.11B | · | $2.69B | |
| Inventory | $280M | $146M | $153M | $332M | $240M | $128M | $117M | $412M | $399M | $295M | · | $487M | $715M | $732M | · | $2.08B | |
| Prepaid Expense | $380M | $348M | $408M | $716M | $764M | $585M | $599M | $823M | $611M | $645M | · | $873M | $1.19B | $1.35B | · | $1.18B | |
| Other Current Assets | $42M | $51M | $45M | $56M | $57M | $69M | $58M | $46M | $31M | $68M | · | $96M | $53M | $64M | · | $85M | |
| Current Assets | $5.82B | $5.77B | $6.54B | $6.60B | $6.17B | $6.77B | $8.10B | $9.67B | $9.66B | $9.60B | · | $10.80B | $10.60B | $12.12B | · | $14.30B | |
| Goodwill | $52M | $52M | $52M | $52M | $52M | $52M | $52M | $52M | $52M | $52M | · | $52M | $52M | $52M | · | · | |
| Intangibles | $109M | $116M | $45M | $47M | $48M | $49M | $40M | $41M | $42M | $43M | · | $45M | $46M | $48M | · | · | |
| Other Non-current Assets | $618M | $675M | $605M | $530M | $546M | $556M | $594M | $556M | $641M | $650M | · | $661M | $1.29B | $1.16B | · | $38M | |
| Total Assets | $10.96B | $11.49B | $12.34B | $12.13B | $12.01B | $12.70B | $14.14B | $15.80B | $15.68B | $16.73B | · | $19.45B | $21.88B | $24.12B | · | $26.06B | |
| Accounts Payable | $167M | $161M | $317M | $267M | $175M | $226M | $405M | $373M | $279M | $183M | · | $494M | $310M | $389M | · | $330M | |
| Accrued Liabilities | $1.91B | $1.91B | $1.39B | $1.18B | $987M | $1.00B | $1.43B | $1.38B | $1.33B | $1.40B | · | $2.22B | $1.49B | $1.61B | · | $1.86B | |
| Current Liabilities | $2.53B | $2.40B | $1.99B | $1.68B | $1.57B | $1.60B | $2.21B | $2.20B | $2.36B | $2.38B | · | $4.38B | $3.12B | $3.50B | · | $6.81B | |
| Capital Leases | $638M | $645M | $653M | $660M | $666M | $667M | $671M | $679M | $668M | $637M | · | $697M | $104M | $96M | · | $79M | |
| Deferred Tax | $255M | $253M | $249M | $239M | $237M | $234M | $231M | $241M | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $284M | $283M | $285M | $281M | $276M | $274M | $267M | $276M | $266M | $262M | · | $172M | $173M | $163M | · | $81M | |
| Total Liabilities | $4.20B | $4.08B | $3.69B | $2.81B | $2.61B | $2.64B | $3.24B | $3.88B | $3.97B | $3.91B | · | $6.00B | $4.93B | $5.26B | · | $8.06B | |
| Total Debt | $591M | $590M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Paid-in Capital | $1.64B | $1.50B | $1.38B | $1.25B | $1.13B | $982M | $866M | $751M | $631M | $487M | · | $277M | $193M | $731M | · | $1.49B | |
| Retained Earnings | $5.10B | $5.88B | $7.22B | $8.05B | $8.25B | $9.07B | $10.04B | $11.16B | $11.15B | $12.43B | · | $13.39B | $17.02B | $18.40B | · | $16.86B | |
| AOCI | $19M | $25M | $45M | $27M | $23M | $10M | $-10M | $11M | $-71M | $-101M | · | $-211M | $-263M | $-267M | · | $-351M | |
| Stockholders' Equity | $6.76B | $7.41B | $8.65B | $9.33B | $9.40B | $10.07B | $10.90B | $11.93B | $11.71B | $12.82B | $13.85B | $13.46B | $16.95B | $18.86B | $19.12B | $17.99B | |
| Liabilities + Equity | $10.96B | $11.49B | $12.34B | $12.13B | $12.01B | $12.70B | $14.14B | $15.80B | $15.68B | $16.73B | · | $19.45B | $21.88B | $24.12B | · | $26.06B | |
| Shares Outstanding | 399,000,000 | 397,000,000 | 394,000,000 | 391,000,000 | 389,000,000 | 387,000,000 | 386,000,000 | 385,000,000 | 384,000,000 | 383,000,000 | 382,000,000 | 381,000,000 | 381,000,000 | 384,000,000 | 385,000,000 | 387,000,000 |
नकदी प्रवाह 12
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $56M | $56M | $66M | $51M | $56M | $38M | $59M | $51M | $40M | $35M | $203M | $246M | $90M | $78M | $80M | $113M | |
| Stock-based Comp | $120M | $104M | $113M | $125M | $130M | $115M | $104M | $112M | $112M | $101M | $79M | $77M | $74M | $75M | $62M | $70M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-105M | $-97M | |
| Other Non-cash | · | $553M | · | · | · | $-219M | · | · | · | $50M | · | · | · | $-1.46B | · | · | |
| Operating Cash Flow | $-526M | $-630M | $930M | $-847M | $-919M | $-1.04B | $825M | $-1.57B | $-1.27B | $-989M | $622M | $-1.60B | $-915M | $-1.23B | $1.66B | $252M | |
| CapEx | $37M | $62M | $39M | $33M | $3M | $117M | $522M | $151M | $182M | $196M | $220M | $140M | $234M | $113M | $92M | $89M | |
| Investing Cash Flow | $329M | $-76M | $-48M | $700M | $564M | $730M | $-539M | $721M | $1.65B | $118M | $-538M | $789M | $1.94B | $2.01B | $-1.05B | $945M | |
| Stock Repurchased | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $-1M | $628M | $526M | $402M | $1.01B | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-526M | · | · | |
| Financing Cash Flow | $14M | $17M | $581M | $-1M | $9M | $4M | $-3M | $11M | $34M | $14M | $-109M | $-58M | $-668M | $-542M | $-438M | $-1.04B | |
| Net Change in Cash | $-185M | $-688M | $1.46B | $-147M | $-345M | $-303M | $282M | $-833M | $409M | $-857M | $-25M | $-869M | $361M | $244M | $176M | $156M | |
| Free Cash Flow | · | $-692M | · | · | · | $-1.15B | · | · | · | $-1.19B | · | · | · | $-1.34B | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -562.1% | -356.8% | · | -25.6% | -638.7% | -972.2% | · | -3.8% | -565.6% | -758.1% | · | -109.9% | -542.7% | -19.7% | · | 34.7% | |
| Net Margin | -539.3% | -345.2% | · | -19.7% | -581.0% | -899.1% | · | 0.70% | -530.7% | -703.6% | · | -198.2% | -401.2% | 4.2% | · | 31.0% | |
| Pretax Margin | -529.0% | -342.9% | · | -18.4% | -576.1% | -892.6% | · | 1.1% | -530.7% | -697.6% | · | -106.9% | -508.4% | -16.4% | · | 36.2% | |
| EBITDA Margin | -523.4% | -342.4% | · | -20.6% | -599.3% | -937.0% | · | -1.0% | -549.0% | -737.1% | · | -96.5% | -516.6% | -15.5% | · | 38.0% | |
| ROA | -6.8% | -11.1% | · | -1.4% | -6.0% | -6.6% | · | 0.07% | -6.8% | -5.8% | · | -16.0% | -5.8% | 0.31% | · | 4.4% | |
| ROE | -9.7% | -15.4% | · | -1.9% | -7.8% | -8.5% | · | 0.10% | -8.9% | -7.4% | · | -23.1% | -7.9% | 0.44% | · | 7.4% | |
| ROIC | -11.3% | -17.5% | · | -3.0% | -9.7% | -10.5% | · | -0.36% | -11.6% | -10.0% | · | -27.7% | -8.7% | 0.50% | · | 5.5% |
तरलता और शोधन क्षमता 4
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | · | 3.9 | 3.9 | 4.2 | · | 4.4 | 4.1 | 4.0 | · | 2.5 | 3.4 | 3.5 | · | 2.1 | |
| Quick Ratio | 0.7 | 0.8 | · | 1.3 | 0.8 | 1.1 | · | 1.5 | 1.1 | 0.9 | · | 1.1 | 1.3 | 1.3 | · | 0.8 | |
| Debt / Equity | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
दक्षता 3
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.4 | 7.0 | · | 0.6 | 0.4 | 0.4 | · | 1.1 | 0.2 | 0.2 | · | 1.7 | 0.6 | 0.6 | · | 0.7 | |
| Receivables Turnover | 5.5 | 5.2 | · | 0.8 | 1.4 | 1.0 | · | 1.1 | 1.2 | 0.3 | · | 0.8 | 0.2 | 0.9 | · | 1.2 |
मूल्यांकन (TTM) 14
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.69B | $1.66B | · | $3.13B | $2.35B | $2.38B | · | $4.10B | $2.58B | $4.20B | · | $7.40B | $10.32B | $16.04B | · | $19.15B | |
| Net Income TTM | $-3.15B | $-3.34B | · | $-1.98B | $-3.06B | $-3.41B | · | $-6.07B | $-7.46B | $-6.11B | · | $-3.89B | $1.94B | $6.98B | · | $10.23B | |
| Market Cap | $27.94B | $20.17B | · | $10.10B | $10.73B | $10.97B | · | $25.73B | $45.60B | $40.81B | · | $39.35B | $46.29B | $58.97B | · | $45.76B | |
| Enterprise Value | $26.81B | $18.85B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -8.7 | -5.9 | · | -5.0 | -3.5 | -3.2 | · | -4.2 | -6.1 | -6.6 | · | -9.9 | 28.0 | 9.3 | · | 4.9 | |
| P/S | 16.5 | 12.2 | · | 3.2 | 4.6 | 4.6 | · | 6.3 | 17.7 | 9.7 | · | 5.3 | 4.5 | 3.7 | · | 2.4 | |
| P/B | 4.1 | 2.7 | · | 1.1 | 1.1 | 1.1 | · | 2.2 | 3.9 | 3.2 | · | 2.9 | 2.7 | 3.1 | · | 2.5 | |
| P / Tangible Book | 4.2 | 2.8 | · | 1.1 | 1.2 | 1.1 | · | 2.2 | 3.9 | 3.2 | · | 2.9 | 2.7 | 3.1 | · | 2.5 | |
| P / Cash Flow | · | -32.0 | · | · | · | -10.6 | · | · | · | -41.3 | · | · | · | -48.1 | · | · | |
| P / FCF | · | -29.1 | · | · | · | -9.5 | · | · | · | -34.4 | · | · | · | -44.1 | · | · | |
| EV / EBITDA | -35.3 | -14.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | -27.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 15.8 | 11.4 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -11.4% | -16.9% | · | -19.9% | -28.8% | -31.4% | · | -23.8% | -16.5% | -15.0% | · | -10.1% | 3.6% | 10.8% | · | 20.3% |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| राजस्व | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B |
| परिचालन मार्जिन % | -158.1% | -121.9% | -61.9% | 48.9% | 72.0% |
| शुद्ध आय | $-2.82B | $-3.56B | $-4.71B | $8.36B | $12.20B |
| तनुकरणित EPS | $-7.26 | $-9.28 | $-12.33 | $20.12 | $28.29 |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| ऋण / इक्विटी | 0.1 | — | — | — | — |
| वर्तमान अनुपात | 3.3 | 3.7 | 3.4 | 2.7 | 1.8 |
| त्वरित अनुपात | 1.4 | 1.0 | 1.3 | 0.9 | 1.1 |
नकदी प्रवाह
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $-2.06B | $-4.05B | $-3.83B | $4.58B | $13.34B |
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
- Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?
- क्या आपको 5 अगस्त से पहले Moderna खरीदना चाहिए?
- MRNA स्टॉक अलर्ट: हंटावायरस वैक्सीन की उम्मीदों पर मॉडर्ना में उछाल
- टीका व्यापार वापस? मॉडर्ना हेंटावायरस शॉट पर काम कर रही है जिससे शेयर बढ़ रहे हैं
- Moderna राजस्व अनुमानों को मजबूत अंतरराष्ट्रीय COVID वैक्सीन बिक्री पर मात देता है
- 3 कंपनियाँ COVID टीकों पर अपनी संपत्ति बनाने में सफल रहीं, लेकिन केवल 1 के पास आगे क्या है इसकी वास्तविक योजना है
- महत्वपूर्ण शुक्रवार विकल्प गतिविधि: CRWD, MRNA, KODK
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 905 फाइलर्स · $16.1B कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 154 (-9 पिछली तिमाही की तुलना में) | 75 (-6 पिछली तिमाही की तुलना में) | 244 (-10 पिछली तिमाही की तुलना में) | 273 (+54 पिछली तिमाही की तुलना में) | +21.6M |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| FMR LLC | $2740775945 | 39137169 | 17.05% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $1625311704 | 23208792 | 10.11% | शेयर |
| Capital World Investors | $1560053964 | 22276996 | 9.70% | शेयर |
| STATE STREET CORP | $1101305296 | 15726193 | 6.85% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1091159349 | 15581313 | 6.79% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $597447261 | 8548380 | 3.72% | शेयर |
| TWO SIGMA INVESTMENTS, LP | $503762906 | 7193530 | 3.13% | शेयर |
| Flagship Pioneering, LLC | $324114597 | 4628225 | 2.02% | शेयर |
| BNP PARIBAS FINANCIAL MARKETS | $306529714 | 4377120 | 1.91% | शेयर |
| JANE STREET GROUP, LLC | $290778566 | 4152200 | 1.81% | पुट ऑप्शन |
| TWO SIGMA ADVISERS, LP | $227948853 | 7729700 | 1.42% | शेयर |
| JANE STREET GROUP, LLC | $214536905 | 3063500 | 1.33% | कॉल ऑप्शन |
| CITADEL ADVISORS LLC | $211924786 | 3026200 | 1.32% | कॉल ऑप्शन |
| NORGES BANK | $211915962 | 3026074 | 1.32% | शेयर |
| CITADEL ADVISORS LLC | $203913354 | 2911800 | 1.27% | पुट ऑप्शन |
| BANQUE PICTET & CIE SA | $189039122 | 2699402 | 1.18% | शेयर |
| WELLINGTON MANAGEMENT GROUP LLP | $167217424 | 2387797 | 1.04% | शेयर |
| Merck & Co., Inc. | $161642545 | 2308190 | 1.01% | शेयर |
| BAMCO INC /NY/ | $139316702 | 1989386 | 0.87% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $139193519 | 1987627 | 0.87% | शेयर |
| DIMENSIONAL FUND ADVISORS LP | $137687594 | 1966124 | 0.86% | शेयर |
| LMR Partners LLP | $136117311 | 1943700 | 0.85% | पुट ऑप्शन |
| Toroso Investments, LLC | $115364880 | 3912000 | 0.72% | कॉल ऑप्शन |
| Theleme Partners LLP | $107960979 | 1541639 | 0.67% | शेयर |
| D. E. Shaw & Co., Inc. | $101368425 | 1447500 | 0.63% | कॉल ऑप्शन |
| D. E. Shaw & Co., Inc. | $97565796 | 1393200 | 0.61% | पुट ऑप्शन |
| Douglas Lane & Associates, LLC | $94083834 | 1343479 | 0.59% | शेयर |
| BlackRock, Inc. | $84628524 | 1208461 | 0.53% | शेयर |
| GOLDMAN SACHS GROUP INC | $80055544 | 1143161 | 0.50% | शेयर |
| BAILLIE GIFFORD & CO | $74054554 | 1057469 | 0.46% | शेयर |
| PERCEPTIVE ADVISORS LLC | $70030000 | 1000000 | 0.44% | पुट ऑप्शन |
| Allianz Asset Management GmbH | $68082956 | 972197 | 0.42% | शेयर |
| Qube Research & Technologies Ltd | $63536422 | 907157 | 0.40% | शेयर |
| Amundi | $62241193 | 888779 | 0.39% | शेयर |
| VANGUARD GROUP INC | $57431598 | 1947494 | 0.36% | शेयर |
| RHUMBLINE ADVISERS | $56713913 | 809853 | 0.35% | शेयर |
| BARCLAYS PLC | $55557809 | 793343 | 0.35% | शेयर |
| Lingotto Investment Management LLP | $53496407 | 763907 | 0.33% | शेयर |
| Vanguard Global Advisers, LLC | $51680249 | 737973 | 0.32% | शेयर |
| LETKO, BROSSEAU & ASSOCIATES INC | $50759845 | 724830 | 0.32% | शेयर |
| Telemark Asset Management, LLC | $49021000 | 700000 | 0.30% | शेयर |
| Step Capital Management Pte. Ltd. | $48670850 | 695000 | 0.30% | शेयर |
| BANK OF AMERICA CORP /DE/ | $48487021 | 692375 | 0.30% | शेयर |
| Swiss National Bank | $47613397 | 679900 | 0.30% | शेयर |
| Walleye Trading LLC | $42165063 | 602100 | 0.26% | पुट ऑप्शन |
| Pictet Asset Management Holding SA | $42018569 | 602512 | 0.26% | शेयर |
| Alyeska Investment Group, L.P. | $39274155 | 560819 | 0.24% | शेयर |
| Trexquant Investment LP | $35376355 | 505160 | 0.22% | शेयर |
| Affinity Asset Advisors, LLC | $35015000 | 500000 | 0.22% | पुट ऑप्शन |
| California Public Employees Retirement System | $34719894 | 495786 | 0.22% | शेयर |
| OFI INVEST ASSET MANAGEMENT | $33559089 | 547881 | 0.21% | शेयर |
| Affinity Asset Advisors, LLC | $33264250 | 475000 | 0.21% | कॉल ऑप्शन |
| Susquehanna Portfolio Strategies, LLC | $32987141 | 471043 | 0.21% | शेयर |
| UBS Group AG | $32164779 | 459300 | 0.20% | पुट ऑप्शन |
| Mount Capital Ltd | $32066737 | 457900 | 0.20% | शेयर |
| Mitsubishi UFJ Asset Management Co., Ltd. | $31516021 | 450036 | 0.20% | शेयर |
| LMR Partners LLP | $30813200 | 440000 | 0.19% | कॉल ऑप्शन |
| MILLENNIUM MANAGEMENT LLC | $30716208 | 438615 | 0.19% | शेयर |
| Ikarian Capital, LLC | $28012000 | 400000 | 0.17% | पुट ऑप्शन |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $27106792 | 387074 | 0.17% | शेयर |
| Caption Management, LLC | $25490920 | 364000 | 0.16% | कॉल ऑप्शन |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $25054913 | 357774 | 0.16% | शेयर |
| VANGUARD ASSET MANAGEMENT, Ltd | $23116133 | 330089 | 0.14% | शेयर |
| Squarepoint Ops LLC | $22479630 | 321000 | 0.14% | पुट ऑप्शन |
| TD Asset Management Inc | $22278084 | 318122 | 0.14% | शेयर |
| Squarepoint Ops LLC | $21912387 | 312900 | 0.14% | कॉल ऑप्शन |
| Caption Management, LLC | $21884375 | 312500 | 0.14% | पुट ऑप्शन |
| Candriam S.C.A. | $21632163 | 309196 | 0.13% | शेयर |
| Alphadyne Asset Management LP | $21527222 | 307400 | 0.13% | पुट ऑप्शन |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $21143948 | 301927 | 0.13% | शेयर |
| CITIGROUP INC | $21009000 | 300000 | 0.13% | कॉल ऑप्शन |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $20685252 | 407190 | 0.13% | शेयर |
| ALLIANCEBERNSTEIN L.P. | $20218654 | 398005 | 0.13% | शेयर |
| CWM, LLC | $19654850 | 386906 | 0.12% | शेयर |
| CAPITAL FUND MANAGEMENT S.A. | $19451392 | 277758 | 0.12% | शेयर |
| ALGERT GLOBAL LLC | $19245645 | 274820 | 0.12% | शेयर |
| Leonteq Securities AG | $18707184 | 267131 | 0.12% | शेयर |
| WOLVERINE TRADING, LLC | $17677807 | 697900 | 0.11% | कॉल ऑप्शन |
| UBS Group AG | $17173177 | 245226 | 0.11% | कॉल ऑप्शन |
| PLUSTICK MANAGEMENT LLC | $17157350 | 245000 | 0.11% | शेयर |
| Legal & General Group Plc | $17134800 | 244678 | 0.11% | शेयर |
| Walleye Trading LLC | $16534083 | 236100 | 0.10% | कॉल ऑप्शन |
| Qube Research & Technologies Ltd | $16190936 | 231200 | 0.10% | कॉल ऑप्शन |
| UBS Group AG | $15978395 | 228165 | 0.10% | शेयर |
| CREDIT AGRICOLE S A | $15887986 | 226874 | 0.10% | शेयर |
| Woodline Partners LP | $15380969 | 219634 | 0.10% | शेयर |
| Quantinno Capital Management LP | $15379041 | 219606 | 0.10% | शेयर |
| CANADA PENSION PLAN INVESTMENT BOARD | $14972974 | 213808 | 0.09% | शेयर |
| NEW YORK STATE COMMON RETIREMENT FUND | $14797339 | 211300 | 0.09% | शेयर |
| STRS OHIO | $14697476 | 209874 | 0.09% | शेयर |
| STATE OF WISCONSIN INVESTMENT BOARD | $14545581 | 207705 | 0.09% | शेयर |
| GROUP ONE TRADING LLC | $14280167 | 203915 | 0.09% | शेयर |
| Qube Research & Technologies Ltd | $13662853 | 195100 | 0.08% | पुट ऑप्शन |
| VAN ECK ASSOCIATES CORP | $13302269 | 189951 | 0.08% | शेयर |
| TWIN FOCUS CAPITAL PARTNERS, LLC | $12997638 | 185601 | 0.08% | शेयर |
| WOLVERINE TRADING, LLC | $12948696 | 511200 | 0.08% | पुट ऑप्शन |
| Jain Global LLC | $12693918 | 181264 | 0.08% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $12206229 | 174300 | 0.08% | पुट ऑप्शन |
| PRUDENTIAL FINANCIAL INC | $11814831 | 168711 | 0.07% | शेयर |
| Chevy Chase Trust Holdings, LLC | $11556911 | 165028 | 0.07% | शेयर |
कंपनी के अंदरूनी सूत्र 29 इनसाइडर्स · 12 अधिकारी · 14 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| James M Mock | Chief Financial Officer | 2 जुलाई 2026 M | 66436 | 0 | 0 | $0 |
| David W Meline | Chief Financial Officer | 9 अगस्त 2022 M | 2857 | 0 | 0 | $0 |
| Lorence H. Kim | Chief Financial Officer | 15 मई 2020 S | 1219910 | 0 | 0 | $0 |
| Stephen Hoge | President | 15 जुलाई 2026 M | 1483848 | 0 | 2 | $-6345384 |
| Soria Ester Banque | Chief Commercial Officer | 5 जुलाई 2026 A | — | 0 | 0 | $0 |
| Shannon Thyme Klinger | Chief Legal Officer | 4 जून 2026 F | 67468 | 0 | 1 | $-173550 |
| Arpa Garay | Chief Commercial Officer | 5 दिसमबर 2023 M | 3690 | 0 | 0 | $0 |
| Juan Andres | Chief Technical Operations and Quality Officer | 28 दिसमबर 2022 M | 12803 | 0 | 0 | $0 |
| Paul Burton | Chief Medical Officer | 4 नवमबर 2022 M | 954 | 0 | 0 | $0 |
| Lori M. Henderson | General Counsel and Secretary | 27 मई 2021 M | 901 | 0 | 0 | $0 |
| Corinne Le Goff | Chief Commercial Officer | 1 फ़रवरी 2021 A | — | 0 | 0 | $0 |
| Jennifer Ling Lee | Chief Accounting Officer | 9 मार्च 2020 S | 4419 | 0 | 0 | $0 |
| Michael R. Mcdonnell | निदेशक | 8 जुलाई 2026 A | — | 0 | 0 | $0 |
| AFEYAN NOUBAR | निदेशक | 21 मई 2026 M | 3924 | 0 | 2 | $-1137065 |
| David M. Rubenstein | निदेशक | 5 अगस्त 2025 M | 1527 | 0 | 0 | $0 |
| Abbas Hussain | निदेशक | 11 जून 2025 S | 580 | 0 | 0 | $0 |
| Sandra Horning | निदेशक | 30 अप्रैल 2025 A | 2352 | 0 | 0 | $0 |
| Elizabeth G Nabel | निदेशक | 30 अप्रैल 2025 A | 3084 | 0 | 0 | $0 |
| Francois Nader | निदेशक | 30 अप्रैल 2025 A | 20607 | 0 | 0 | $0 |
| Elizebeth E Tallett | निदेशक | 30 अप्रैल 2025 A | 703 | 0 | 0 | $0 |
| Paul Sagan | निदेशक | 30 अप्रैल 2025 A | 312027 | 0 | 0 | $0 |
| Stephen Berenson | निदेशक | 6 मई 2024 A | 22203 | 0 | 0 | $0 |
| Robert Langer | निदेशक | 6 मई 2024 A | 11467664 | 0 | 0 | $0 |
| Moncef Slaoui | निदेशक | 29 अप्रैल 2020 A | — | 0 | 0 | $0 |
| Peter Barton Hutt | निदेशक | 20 नवमबर 2019 M | 3924 | 0 | 0 | $0 |
| Israel Ruiz | निदेशक | 27 जून 2019 A | 4559 | 0 | 0 | $0 |
| Edwin M Kania JR | 10% मालिक | 14 जनवरी 2020 S | 23847 | 0 | 0 | $0 |
| Stephane Bancel | — | 6 अगस्त 2026 M | 6440260 | 0 | 4 | $-28715011 |
| Tal Zvi Zaks | — | 30 जून 2021 M | 0 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
ईटीएफ स्वामित्व 134 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| FIVY · Tidal Trust II | 7.08% | 7642 NS | 30 अप्रैल 2026 | N-PORT |
| IDNA · iShares Trust | 3.98% | 145819 SH | 8 अगस्त 2026 | दैनिक |
| GNOM · Global X Funds | 3.28% | 38755 NS | 31 मई 2026 | N-PORT |
| BBP · ETFis Series Trust I | 2.49% | 32122 NS | 30 अप्रैल 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2.11% | 18282 NS | 31 मई 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1.97% | 82159 SH | 8 अगस्त 2026 | दैनिक |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.95% | 257758 SH | 8 अगस्त 2026 | दैनिक |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1.60% | 21593 SH | 8 अगस्त 2026 | दैनिक |
| IBB · iShares Trust | 1.51% | 2668045 SH | 8 अगस्त 2026 | दैनिक |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.30% | 15139 NS | 30 अप्रैल 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 1.16% | 185105 SH | 8 अगस्त 2026 | दैनिक |
| NUSC · Nushares ETF Trust | 1.05% | 293839 NS | 30 अप्रैल 2026 | N-PORT |
| BIB · ProShares Trust | 0.94% | 14600 NS | 31 मई 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0.90% | 6141 NS | 31 मई 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.77% | 86741 NS | 30 अप्रैल 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.68% | 46782 NS | 30 अप्रैल 2026 | N-PORT |
| PDP · Invesco Exchange-Traded Fund Trust | 0.67% | 169402 SH | 8 अगस्त 2026 | दैनिक |
| HIBL · Direxion Shares ETF Trust | 0.54% | 9339 NS | 30 अप्रैल 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0.53% | 5199246 SH | 8 अगस्त 2026 | दैनिक |
| SPXD · DBX ETF Trust | 0.46% | 666 NS | 31 मई 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.41% | 55196 NS | 30 अप्रैल 2026 | N-PORT |
| TECB · iShares Trust | 0.40% | 35820 SH | 8 अगस्त 2026 | दैनिक |
| CGGR · Capital Group Growth ETF | 0.39% | 2018912 NS | 31 मई 2026 | N-PORT |
| SMLF · iShares Trust | 0.35% | 275284 SH | 8 अगस्त 2026 | दैनिक |
| IYH · iShares Trust | 0.32% | 218273 SH | 8 अगस्त 2026 | दैनिक |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.32% | 139893 NS | 30 अप्रैल 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0.30% | 940344 NS | 31 मई 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0.30% | 38636 NS | 30 अप्रैल 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0.30% | 8190431 SH | 8 अगस्त 2026 | दैनिक |
| VHT · VANGUARD WORLD FUND | 0.30% | 864043 SH | 8 अगस्त 2026 | दैनिक |
| ESML · iShares Trust | 0.28% | 150526 SH | 8 अगस्त 2026 | दैनिक |
| VFMO · VANGUARD WELLINGTON FUND | 0.28% | 79787 SH | 8 अगस्त 2026 | दैनिक |
| IMCV · iShares Trust | 0.27% | 56623 SH | 8 अगस्त 2026 | दैनिक |
| FHLC · FIDELITY COVINGTON TRUST | 0.26% | 162167 NS | 30 अप्रैल 2026 | N-PORT |
| GINN · Goldman Sachs ETF Trust | 0.25% | 11129 NS | 31 मई 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0.24% | 4036776 SH | 8 अगस्त 2026 | दैनिक |
| IXJ · iShares Trust | 0.24% | 185275 SH | 8 अगस्त 2026 | दैनिक |
| RXL · ProShares Trust | 0.24% | 3623 NS | 31 मई 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.23% | 6933 NS | 30 अप्रैल 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0.19% | 16705 NS | 31 मई 2026 | N-PORT |
| GSEW · Goldman Sachs ETF Trust | 0.19% | 71183 NS | 31 मई 2026 | N-PORT |
| IWS · iShares Trust | 0.19% | 549015 SH | 8 अगस्त 2026 | दैनिक |
| PRF · Invesco Exchange-Traded Fund Trust | 0.18% | 311100 SH | 8 अगस्त 2026 | दैनिक |
| WSML · iShares Trust | 0.17% | 20513 SH | 8 अगस्त 2026 | दैनिक |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.16% | 352 NS | 31 मई 2026 | N-PORT |
| SFGV · EA Series Trust | 0.16% | 38316 NS | 29 मई 2026 | N-PORT |
| FNDX · SCHWAB STRATEGIC TRUST | 0.15% | 818606 NS | 31 मई 2026 | N-PORT |
| FNDB · SCHWAB STRATEGIC TRUST | 0.14% | 39358 NS | 31 मई 2026 | N-PORT |
| IWR · iShares Trust | 0.14% | 1481489 SH | 8 अगस्त 2026 | दैनिक |
| FLCV · Federated Hermes ETF Trust | 0.14% | 2758 NS | 31 मई 2026 | N-PORT |